Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Shahin Davoudpour, PhD, MA, MA, talked with Physician’s Weekly about using social network strategies to improve pre-exposure prophylaxis awareness and uptake.

Nearly 40 million individuals globally are currently living with HIV, a virus that has resulted in the loss of over 42 ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is ...

The department of virology & immunology, SIAHS, Srinivas University, successfully organized a National online webinar titled ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

US antivirals specialist Gilead Sciences today announced a strategic partnership agreement with the Global Fund to Fight AIDS ...

National HIV Testing Day has raised awareness and confront stereotypes about HIV. Learn about HIV testing options and ...

More than 600 individuals and organizations from across Ontario have signed a letter calling on the province to allow the distribution of syringes at Homelessness and Addiction Recovery Treatment ...